Verification of methodology for 3D analysis of pharmaceutically relevant biomolecules at the atomic scale
| Reference number | |
| Coordinator | Vitroprobe Analytics AB |
| Funding from Vinnova | SEK 250 000 |
| Project duration | August 2020 - July 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2020 |
Important results from the project
** Denna text är maskinöversatt ** The objective project was to verify a new technology for analysis of biomolecules on an atomic scale. This would be done through a collaboration with a pharmaceutical company, where a pharmacologically interesting target molecule for drugs would be investigated and structured. Due to the pandemic, the project has been delayed and the samples have been delivered for analysis during the month of May. The analyzes are expected to be completed after the summer. In the meantime, method development has taken place to increase technology reliability.
Expected long term effects
** Denna text är maskinöversatt ** Although structural analysis of the target protein has not yet been possible, Vitroprobe has deepened its collaboration with the pharmaceutical company. This is an important step in building confidence in the technology and demonstrating its capabilities. In addition to this, a new platform for higher throughput of samples has been developed and will be used during the summer. Vitroprobe has also been granted entry into the incubator company Chalmers Ventures Acceleratorprogram and thus has even better conditions to grow.
Approach and implementation
** Denna text är maskinöversatt ** As the planned delivery of samples was delayed due to the pandemic, the focus has shifted to method development. This has given Vitroprobe space to sharpen the sample preparation process and supplement with electron microscopy. This means that the company will be able to handle a larger amount of samples in future project.